ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction

R. Hod Dvorai1, R. Lee2, P. Muluhngwi2, M. Raijmakers3, A. Shetty2, A. Tambur2, M. Ison2

1Department of Pathology, SUNY Upstate Medical University, Syracuse, NY, 2Northwestern University, Chicago, IL, 3University of Santiago, Santiago, Chile

Meeting: 2020 American Transplant Congress

Abstract number: D-182

Keywords: Antibodies, Polyma virus, Rejection

Session Information

Session Name: Poster Session D: Kidney: Polyoma

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: To evaluate development of de novo donor specific antibodies (dnDSA) in Renal Transplant Recipients (RTR) with immunosuppression (IS) modulation due to BK viremia (BKV) and the associated risk of antibody mediated rejection (AMR).

*Methods: We retrospectively collected data from the NM Enterprise Data Warehouse, primary review of biopsies and HLA antibody testing on all RTR 2007-2017 at our center (n=1911). BK case group included pts who develop BKV >10,000 c/ml or biopsy proven BKV and nephropathy (BKVN). DSA and biopsy reports through 1 yr post-dx were included in the analysis. Two matched controls without BKVN or BKV were selected for each case. Controls were matched by gender, donor type and transplant within 1 yr. For BK group, dnDSA was defined as detected only after IS modulation. Per protocol, MMF was reduced initially at the direction of the transplant nephrologist.

*Results: 248/1911 RTR (12.9%) had BKV or BKVN. Of these, 37 (14.9%) developed dnDSA during the 1 yr follow up, with 36/37 (97.29%) developing the dnDSA within 1 yr of tx. Among control group, 37/239 (15.48%) exhibited dnDSA, with the majority of DSA (64.87%) occurring > 1 year post-tx. AMR was diagnosed in 17/203 (8.4%) biopsied BK and 37/445 (8.3%) biopsied control pts. All 17 AMR+ BK pts developed AMR within 1 yr of BK diagnosis (median=143 days). In contrast, 21/37 (56.75%) of control pts developed AMR >1 yr post-tx (median=463 days).

 border=

*Conclusions: nDSA developed after IS reduction for BKVN in a minority of pts but is associated with a risk of AMR. While rates of dnDSA and AMR were similar between cases and controls, dnDSA and AMR was more likely to occur within the 1st yr post-transplant in the BK cases. Further data is needed to determine the rate of dnDSA and AMR in pts with and without BK.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Dvorai RHod, Lee R, Muluhngwi P, Raijmakers M, Shetty A, Tambur A, Ison M. Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/development-of-de-novo-antibody-in-renal-transplant-recipients-with-bk-viremia-managed-with-immunosuppression-reduction-2/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences